Publication:
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects

Simple item page
dc.contributor.authorWang, Yanli
dc.contributor.authorBai, Liang
dc.contributor.authorLin, Yan
dc.contributor.authorGuan, Hua
dc.contributor.authorZhu, Ninghong
dc.contributor.authorChen, Yulong
dc.contributor.authorLi, Yafeng
dc.contributor.authorGao, Shoucui
dc.contributor.authorZhao, Sihai
dc.contributor.authorFan, Jianglin
dc.contributor.authorLiu, Enqi
dc.date.accessioned2019-12-26T10:18:39Z
dc.date.available2019-12-26T10:18:39Z
dc.date.issued2014
dc.description.abstractStatins are often prescribed for treatment of cardiovascular diseases, although there are still many patients who cannot be effectively treated by statins alone. Both probucol and cilostazol exhibit antiatherogenic effects. In the current study, we attempted to investigate whether a probucol and cilostazol combination had any add-on effects on atorvastatin. To examine this hypothesis, we fed Japanese white rabbits with a cholesterol-rich diet supplemented with atorvastatin alone (Statin group), probucol and cilostazol (PC group), atorvastatin, probucol and cilostazol (APC group), and compared their effects on plasma lipids and aortic atherosclerosis. All three drug-treated groups had lowered total cholesterol levels compared with the vehicle group but high-density lipoproteins cholesterol levels of the atorvastatin group were higher than other groups. Although aortic atherosclerosis was significantly reduced in all drug-treated groups, the most prominent atheroprotective effect was seen in APC group (APC: 67% reduction> PC: 43% reduction> Statin group: 42% reduction over the vehicle). Morphometric analysis revealed that the reduced aortic atherosclerosis in all three groups was mainly attributed to the reduction of intimal macrophages and smooth muscle cells. These results suggest that a combination of probucol and cilostazol with statin enhances statin’s anti-atherogenic functions, which may be beneficial for those patients who are less responsive to statin therapy alone.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.identifier.citationHistology and Histopathology, Vol. 29, n.º 12 (2014)
dc.identifier.doihttps://doi.org/10.14670/HH-29.1593
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/84981
dc.languageenges
dc.publisherF. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histologíaes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAtorvastatines
dc.subjectProbucoles
dc.subjectCilostazoles
dc.subjectAtherosclerosises
dc.subject.otherCDU::5 - Ciencias puras y naturales::57 - Biología::576 - Biología celular y subcelular. Citologíaes
dc.titleDemonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effectses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wang-29-1593-1600-2014.pdf
Size:
8.17 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.29, nº12 (2014)